Skip to main content
رجوع
Watch Compare

TherapeuticsMD, Inc.

جودة البيانات: 67%
TXMD
NASDAQ Manufacturing Chemicals
KWD 2.07
▲ KWD 0.02 (0.98%)
القيمة السوقية: 23.50 M
السعر
KWD 2.03
القيمة السوقية
23.50 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-2.08%
أعلى من متوسط القطاع (-54.01%)
ROIC-10.27%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio2.93
Interest Coverage-548.75

التقييم

PE (TTM|NTM)
-41.29 | 5.91
أقل من متوسط القطاع (-1.49)
P/B Ratio0.86
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1385 نظير)
المقياس السهم وسيط القطاع
P/E -41.3 -1.5
P/B 0.9 1.6
ROE % -2.1 -54.0
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

لا تتوفر تقديرات مستقبلية

مفاجآت الأرباح

آخر 4 أرباع
الربع EPS المقدر EPS الفعلي المفاجأة
Q22023 -KWD 0.07 -KWD 0.24 -242.9%
Q12023 KWD 0.06 -KWD 0.24 -500.0%
Q42022 -KWD 1.11 KWD 8.23 +841.4%
Q32022 -KWD 2.04 -KWD 3.13 -53.4%

ETFs Holding This Stock

BRSIX BRSIX
0.03% weight
EMAAX EMAAX
0.00% weight
EMACX EMACX
0.00% weight
EAAAX EAAAX
0.00% weight
EMAYX EMAYX
0.00% weight
GADVX GADVX
0.00% weight
GABCX GABCX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -569,000.0
ROE -2.08% ROA -1.47%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) N/A
ROIC -10.27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.93
Interest Coverage -548.75 Asset Turnover N/A
Working Capital 9.56 M Tangible Book Value 23.53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -41.29 Forward P/E 5.91
P/B Ratio 0.86 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield 16.92%
FCF Yield N/A
Market Cap 23.50 M Enterprise Value 23.50 M
Per Share
EPS (Diluted TTM) -0.05 Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — 1.76 M 1.30 M 69.96 M 86.95 M
Net Income -569,000.0 -2.18 M -10.28 M 112.00 M -172.42 M
EPS (Diluted) -0.05 -0.19 -0.98 11.96 —
Gross Profit — — 1.30 M 68.57 M 68.11 M
Operating Income -4.39 M -4.76 M -8.52 M 1.19 M -139.77 M
EBITDA — — — — —
R&D Expenses — — — — 7.09 M
SG&A Expenses — 4.74 M — — —
D&A 384,000.0 509,000.0 922,000.0 1.19 M 4.09 M
Interest Expense 8,000.0 9,500.0 300,000.0 36.07 M 32.92 M
Income Tax -31,000.0 -31,000.0 -43,000.0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 37.66 M 38.82 M 43.31 M 90.46 M 169.47 M
Total Liabilities 10.78 M 11.45 M 14.02 M 55.32 M 263.09 M
Shareholders' Equity 26.88 M 27.37 M 29.29 M 35.14 M -93.62 M
Total Debt — — — 188.27 M 188.27 M
Cash & Equivalents — 5.06 M — — —
Current Assets 14.45 M 12.26 M 11.80 M 55.35 M 119.47 M
Current Liabilities 4.79 M 5.17 M 6.85 M 46.84 M 252.89 M